Experts Discuss the Safety Profile of Mobocertinib in EGFR Exon 20–Mutated Advanced NSCLC
Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the safety profile of mobocertinib in EGFR exon 20 insertion mutation–positive advanced non–small cell lung cancer.
EP: 1.Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIs
EP: 2.Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs
EP: 3.Dr. Piotrowska on the Management of Paronychia Associated With EGFR TKIs
EP: 4.Best Practices for Managing EGFR Tyrosine Kinase Inhibitor–Related Adverse Events
EP: 5.Experts Discuss Management of Skin and Mouth TRAEs Associated With EGFR TKIs
EP: 6.Experts Discuss the Risk of Skin Toxicities Associated With EGFR TKIs
EP: 7.Experts Discuss Common AEs With EGFR TKIs
EP: 8.Experts Discuss the Safety Profile of Mobocertinib in EGFR Exon 20–Mutated Advanced NSCLC
EP: 9.Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs
EP: 10.Experts Discuss the Management of Paronychia When Treating Patients with EGFR TKIs
EP: 11.Experts on the Management of Diarrhea Associated With EGFR TKIs
Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the safety profile of mobocertinib (Exkivity) in EGFR exon 20 insertion mutation–positive advanced non–small cell lung cancer (NSCLC).
Zosia Piotrowska, MD, is a clinical researcher and lung cancer medical oncologist, Massachusetts General Hospital Cancer Center. Christine Lovly, MD, PhD, is an associate professor of medicine, Division of Hematology-Oncology, an Ingram associate professor of cancer research, and co-leader of Translational Research and Interventional Oncology Program at Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center. Amanda Cass, PharmD, BCPS, is a clinical pharmacist, the Thoracic Oncology Clinic, Vanderbilt University Medical Center.
Piotrowska, Lovly, and Cass explain that mobocertinib is the only EGFR TKI currently approved for advanced NSCLC harboring EGFR exon 20 insertion mutations. A typical adverse effect (AE) associated with EGFR TKIs is diarrhea, including mobocertinib. Approximately 90% of patients who receive mobocertinib experience diarrhea, Piotrowska notes.
The most common AEs of mobocertinib in addition to diarrhea include stomatitis, vomiting, anorexia, weight loss, and rash. More rare toxicities associated with mobocertinib to be aware of include interstitial lung disease/pneumonitis and cardiac toxicity.
